|
![]() |
|||
|
||||
OverviewThe majority of pharmaceutical prescriptions are to patients aged over 55 years, so any new pharmacological substance must be safe for the elderly. Studies of the safety of drugs for the elderly focus on a special subgroup of elderly volunteers with practically no pathological history and who are receiving no medication - the healthy elderly subjects. In order to assess any changes from the norm under medication, it is vital to have hard data on what actually constitutes the norm. This reference provides data on norm values and biological variations for various clinical and laboratory parameters in pharmacological testing in the elderly. Full Product DetailsAuthor: P.R. Heine , Hans-Peter Breuel , J. Kuhlmann , J. HorkulakPublisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG Imprint: Springer-Verlag Berlin and Heidelberg GmbH & Co. K Edition: Softcover reprint of the original 1st ed. 1996 Dimensions: Width: 15.50cm , Height: 1.00cm , Length: 23.50cm Weight: 0.400kg ISBN: 9783540594956ISBN 10: 3540594957 Pages: 182 Publication Date: 01 December 1995 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Out of stock ![]() The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available. Table of Contents1 Introduction.- 2 Theories of Aging.- 3 Changes in Body Functions, Pharmacokinetics, and Receptor Sensitivity with Age.- 3.1 Changes in Central Nervous System.- 3.2 Cardiovascular and Pulmonary Changes.- 3.3 Changes in Clinical Chemistry and Hematology.- 3.4 Changes in Pharmacokinetics.- 3.5 Changes in Receptor Sensitivity.- 4 Practical Aspects in Performing Clinical Trials in Elderly Subjects.- 4.1 Recruitment of Subjects.- 4.2 Performance of the Study.- 4.3 Safety Aspects.- 4.4 Sample Size.- 4.5 Compliance of Subjects with Medication and Study Regulations.- 5 Experimental Findings in Elderly Subjects.- 5.1 Method.- 5.2 Experimental Data.- 5.3 Consequences from Experimental Data in Healthy Subjects.- 6 Statistical Details.- 6.1 Blood Pressure.- 6.2 Ambulatory Blood Pressure Monitoring.- 6.3 ECG Times.- 6.4 Ambulatory ECG Monitoring.- 6.5 Spirometry (FEV1).- 6.6 Clinical Chemistry.- 6.7 Hematology.- References.ReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |